Improve study outcomes for pediatric therapies by addressing the needs of children and their families –
from formulations to biospecimen requirements.
Pediatric expertise is essential to developing and commercializing pediatric therapies, from the earliest planning stages through launch and real-world assessment. With our Pediatric Center of Excellence, we provide a range of scientific, therapeutic, regulatory, and operational expertise to ensure study success.
These resources extend beyond IQVIA to encompass a global network of top performing sites, ensuring there are sites around the world with the proven ability to conduct every pediatric clinical trial.
Conduct thorough independent audits of study documents and processes to identify specific pediatric considerations and safeguard the well-being of children in research.
Utilize pharmacokinetic modeling and simulations to minimize lab procedures for children, which reduces anxiety and increases retention.
Drug formulations that are palatable to young children, such as dispersible and mini tablets, improve adherence and safety among patients.
IQVIA CTEs help onboard patients into studies, share expertise, and advocate for them and their families, which improve outcomes.
Offer the flexibility and convenience of hybrid and decentralized clinical trial modalities to reduce burden for pediatric patients and their families.
Navigate the landscape of consent regulations that vary by age and country, and demonstrate concern for patient rights, privacy and custody issues.
Collaborate with PAGs to raise study awareness and facilitate patient and family participation in aspects of studies including protocol design and relevant endpoints.
Successful pediatric trial designs are attentive to the needs of infant, child, or adolescent patients. And decision making about study participation typically involves multiple family members.
IQVIA considers the differences within pediatric sub-populations and takes a sensitive approach to these patients and their caregivers.
activated for various pediatric trials
implemented in 101 countries since 2018
in studies, including pediatric patients
published by IQVIA, including six in oncology and seven in immunology
Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.
Identify the best performing sites for your trial in less time with new machine learning and predictive modeling methods.
Bring trials directly to patients to improve access and engagement, increase quality and shorten timelines.
.svg){kind=icon}
